Globally, breast cancer (BC) was the most commonly diagnosed malignancy and the leading cause of cancer death among females in 2022.1 The incidence is projected to continue increasing in multiple countries across sub-Saharan Africa (SSA).2-4 SSA has the highest incidence-to-mortality ratio, largely due to 50%-90% of cases being diagnosed with advanced disease and lack of screening.5-7 In many of these settings, BC disproportionately affects women under age 50 years,8,9 and nearly two thirds of patients in SSA are hormone receptor–positive (HR+).10,11. Here, NR4A1 is linked to breast cancer.